NICE Guidelines Set to Reduce Unnecessary Colonoscopies

By HEOR Staff Writer

September 21, 2023

A New Era for Colorectal Cancer Diagnosis

The National Institute for Health and Care Excellence (NICE) has released new guidance that could spare tens of thousands of people the need for a colonoscopy each year. The updated guidelines recommend offering people with signs or symptoms of colorectal cancer a home test using quantitative faecal immunochemical tests (FIT).

These tests, which measure the amount of blood in the faeces, could lead to faster diagnoses and fewer referrals to secondary care for unnecessary colonoscopies. This shift in approach would allow colonoscopy services to focus on the patients who need them most, improving both patient care and healthcare efficiency.

Positive Impact on the NHS and Patient Care

The North Tees and Hartlepool NHS Foundation Trust has already implemented the approach recommended by NICE. They found that they detected more cancers using fewer colonoscopies, which is beneficial for both patients and the NHS.

Mark Chapman, interim director of medical technology and digital evaluation at NICE, said the new recommendations could help around 100,000 people avoid unnecessary colonoscopies. Furthermore, it will free up waiting lists to diagnose those more likely to have colorectal cancer.

Genevieve Edwards, chief executive at Bowel Cancer UK, added that the new guidance would help GPs identify and refer the right patients for further testing quickly, potentially detecting bowel cancer at an earlier stage when it is more treatable and curable.

With colorectal cancer being the fourth most common cancer in the UK, these new guidelines represent a significant step forward in managing its diagnosis and treatment.

Reference url

Recent Posts

Navigating Novo Nordisk Board Changes: Leadership for Growth and Strategy

By João L. Carapinha

October 21, 2025

The Novo Nordisk board changes involve a major restructuring, as the Novo Nordisk Foundation is revitalizing leadership ahead of a general meeting on November 14, 2025, where new directors will be elected. Key candidates include former CEO Lars Rebien Sørensen as chair and Cees de Jong as vice ch...
Keytruda Lung Cancer Treatment: Long-Term Survival Gains in NSCLC

By João L. Carapinha

October 20, 2025

If you're searching for effective options in Keytruda lung cancer treatment, recent data shows pembrolizumab (Keytruda) significantly boosts survival rates in non-small cell lung cancer (NSCLC). In the KEYNOTE-671 trial, this immunotherapy combined with chemotherapy raised five-year overall survi...
Promising PSMA-Targeted Therapy Delays Prostate Cancer Progression
Novartis recently announced pivotal data from the Phase III PSMAddition trial. It demonstrates that PSMA-targeted therapy with Pluvictoâ„¢ (lutetium-177 vipivotide tetraxetan) combined with standard of care (androgen receptor pathway inhibitor plus androgen deprivation therapy) significantly reduce...